ABBV Stock UPDATES Abbvie Inc. Common Stock (ABBV) 63.46 10/31/2014

New Post Public Reply Private Reply Replies (0) Message Board

Oct 31, 2014 at 10:21 PM

Abbvie Inc. Common Stock (ABBV) 63.46 $ABBV

S&P, Dow Close at Record Highs as U.S. Economic Strength Trumps Global Fears
at The Street - Fri Oct 31, 3:19PM CDT
Global woes plagued markets at the outset of October, but markets are poised to close at a record-high amid strong U.S. economic prospects.
SBUX: 75.56 (-1.76), GPRO: 77.10 (+8.85), C: 53.53 (+0.38), XOM: 96.71 (+2.26), ABBV: 63.46 (+2.28), CVX: 119.95 (+2.75)

AbbVie Beats Q3 Earnings Estimates, Raises Guidance
at Investor's Business Daily - Fri Oct 31, 1:25PM CDT
Big pharma AbbVie beat analysts' Q3 estimates and raised its guidance Friday, sending its stock up 4% to an all-time high above 63. AbbVie's (ABBV) earnings rose 9% over the year-earlier quarter to 89 cents a share, 12 cents above analysts'...
IMS: 24.25 (+0.26), GILD: 112.00 (-2.22), SHPG: 199.80 (+0.38), AMGN: 162.18 (+0.60), ABBV: 63.46 (+2.28)

Stock Market Today: October Stock Scare Turns to Rally as Dow Hits Record
at The Street - Fri Oct 31, 12:58PM CDT
Fears of an October stock market slump are a distant memory as central banks print money and the U.S. economy kicks into gear.
SBUX: 75.56 (-1.76), GPRO: 77.10 (+8.85), C: 53.53 (+0.38), XOM: 96.71 (+2.26), ABBV: 63.46 (+2.28), CVX: 119.95 (+2.75)

AbbVie (ABBV) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Fri Oct 31, 12:23PM CDT
The following AbbVie (ABBV) conference call took place on October 31, 2014, 09:00 AM ET. This is a transcript of that earnings call:
ABBV: 63.46 (+2.28)

Stock Market Today: Stocks Hit New Highs as Japan Boosts Stimulus
at The Street - Fri Oct 31, 10:32AM CDT
U.S. stocks surge Friday morning after the Bank of Japan unexpectedly increases its annual stimulus targets.
SBUX: 75.56 (-1.76), GPRO: 77.10 (+8.85), C: 53.53 (+0.38), XOM: 96.71 (+2.26), ABBV: 63.46 (+2.28), CVX: 119.95 (+2.75)

Mylan Rises On Q3 Earnings Beat, Affirms Abbott Deal
at Investor's Business Daily - Fri Oct 31, 10:17AM CDT
Mylan (MYL) was up 3%, near 54, in early trading in the stock market today after the drugmaker beat Q3 estimates late Thursday. Earlier, the stock was up more than 7% at a nearly eight-month high above 56. Earnings came in on the high end of the...
ABT: 43.59 (+0.10), SHPG: 199.80 (+0.38), MYL: 53.55 (+1.18), ABBV: 63.46 (+2.28)

CMK Select Recognized as Women's Business Enterprise
Marketwired - Fri Oct 31, 9:45AM CDT
Since 1997, women-owned businesses have increased in number by 68 percent. CMK Select, a pharmaceuticals business management and consulting services company, is pleased to announce its national certification by the Women's Business Enterprise National Council (WBENC) as a Women's Business Enterprise.
ABBV: 63.46 (+2.28)

AbbVie Q3 Earnings Top on Humira Sales, Boosts Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 9:33AM CDT
AbbVie (ABBV) raised it outlook for 2014 - the new guidance surpassed expectations.
AGN: 190.06 (+0.62), SHPG: 199.80 (+0.38), ABBV: 63.46 (+2.28), BMY: 58.19 (-0.79)

Stock Market News for October 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:10AM CDT
Benchmarks ended in the green zone on Thursday, banking on encouraging third quarter GDP numbers and upbeat quarterly results
JNJ: 107.78 (+0.74), NEE: 100.22 (+0.31), V: 241.43 (+4.78), GILD: 112.00 (-2.22), DUK: 82.15 (-0.14), EXC: 36.59 (-0.11), MRK: 57.94 (+0.63), PFE: 29.95 (+0.11), ABBV: 63.46 (+2.28), DTE: 82.16 (+0.17), SO: 46.36 (-0.09), MA: 83.75 (+0.62)

How AbbVie Inc. Excelled in Third Quarter
Keith Speights, The Motley Fool - Motley Fool - Fri Oct 31, 8:46AM CDT
Make it three in a row. AbbVie beat earnings expectations for the third time this year. The drugmaker announced third-quarter results before the market opened on Friday. Here are the highlights -- and how AbbVie excelled yet again. Source:...
ABBV: 63.46 (+2.28)

Stock Market Today: S&P 500 Is Poised to Open Near Record High on Expanded Bank of Japan Stimulus
at The Street - Fri Oct 31, 7:50AM CDT
U.S. stock futures surge Friday after the Bank of Japan unexpectedly increases its annual stimulus targets by 10 trillion yen to 80 trillion ($717 billion).
SBUX: 75.56 (-1.76), GPRO: 77.10 (+8.85), C: 53.53 (+0.38), XOM: 96.71 (+2.26), ABBV: 63.46 (+2.28), CVX: 119.95 (+2.75)

AbbVie Reports Third-Quarter 2014 Financial Results
PR Newswire - Fri Oct 31, 6:49AM CDT
AbbVie (NYSE: ABBV) today announced financial results for the third quarter ended Sept. 30, 2014.
ABBV: 63.46 (+2.28)

Eli Lilly/Boehringer Ingelheim Restructure Diabetes Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:05PM CDT
Eli Lilly (LLY) and partner Boehringer Ingelheim amended the operational and financial structure of their diabetes collaboration in certain countries.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)

Sanofi Beats on Q3 Earnings but Lantus Outlook Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:45PM CDT
Sanofi reported third-quarter 2014 business earnings of 97 cents per ADS, 3 cents above the Zacks Consensus Estimate.
AGN: 190.06 (+0.62), NVO: 45.18 (-1.03), ABBV: 63.46 (+2.28), SNY: 46.24 (+0.54)

Charles River (CRL) Beats on Q3 Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 11:30AM CDT
Charles River Laboratories (CRL) reported third-quarter 2014 earnings (excluding special items) of 86 cents per share.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), BMY: 58.19 (-0.79), CRL: 63.16 (+0.35)

Will AbbVie (ABBV) Disappoint in this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:28PM CDT
AbbVie (ABBV) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 31.
INCY: 67.06 (+2.88), TEVA: 56.47 (unch), AMAG: 33.01 (-0.95), ABBV: 63.46 (+2.28)

3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 66.92 (+0.63), VRX: 133.04 (+1.53), ACT: 242.74 (-0.47), AMGN: 162.18 (+0.60), TKMR: 16.68 (-0.26), GSK: 45.49 (+0.35), AGN: 190.06 (+0.62), JNJ: 107.78 (+0.74), SHPG: 199.80 (+0.38), MRK: 57.94 (+0.63), INFI: 13.62 (-0.19), ABBV: 63.46 (+2.28), KPTI: 41.08 (+1.03)

Gilead Beats on Q3 Earnings, Sovaldi Sales Fall Sequentially - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:00AM CDT
Gilead Sciences, Inc. reported third-quarter earnings (including stock-based compensation expenses) of $1.79 per share.
AGN: 190.06 (+0.62), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), ABBV: 63.46 (+2.28)

If You Purchased Shire plc American Depository Receipts ("ADRs"

During The Period Of June 20, 2014 And October 14, 2014 And Lost Money, Gardy & Notis, LLP Encourages You To Contact The Law Firm
PR Newswire - Wed Oct 29, 7:38AM CDT
Gardy & Notis, LLP, a national law firm advocating for shareholder rights, is investigating AbbVie Inc. (NYSE: ABBV) and its officers and directors in connection with statements distributed by, or on behalf of, AbbVie to purchasers of Shire plc ADRs (NASDAQ: SHPG) and the general investing public regarding AbbVie's rationale for pursuing a business combination with Shire.
SHPG: 199.80 (+0.38), ABBV: 63.46 (+2.28)

Compliance Notice, Dividend Announcements, New Share Repurchase Program, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Edwards and Lilly
PR Newswire - Wed Oct 29, 7:35AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Edwards Lifesciences Corp. (NYSE: EW) and Eli Lilly and Co. (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7520-100free.
GILD: 112.00 (-2.22), PFE: 29.95 (+0.11), EW: 120.92 (+0.64), LLY: 66.33 (-0.47), ABBV: 63.46 (+2.28)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Axon Body 5: A Leap Forward in AI for Public Safety

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Alaska's Insurance Maze: Coverage Over Cheap Policies

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Darden Faces Class Action Over Reimbursement Failures

Class Action Puts Darden Restaurants in Legal Hot Seat Darden Restaurants, Inc. is staring down the barrel of a lawsuit that's as fiery as a grill on a Saturday night rush. The legal cavalry from Blumenthal Nordrehaug Bhowmik De Blouw LLP has stormed in with a class action complaint, aiming dead center at Darden for allegedly breaching the California Labor Code. In plain...

Aluminum Design Fumble: Geometry Over Wall Thickness

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Spooky Dining at CARNE: A Halloween Hit in Oxnard

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

World Young Scientist Summit 2026 in Wenzhou Kicks Off

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...